XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
XORTX Therapeutics Inc. operates in the Healthcare sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for XRTX.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). XRTX Stock Intelligence Report. [stoxpulse.com/stocks/xrtx]
Disclaimer: The information on this page about XORTX Therapeutics Inc. (XRTX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for XORTX Therapeutics Inc..
Join the WaitlistAI analysis is being generated. Visit the AI Intel tab for detailed analysis.
How Much Would You Have if You Had Invested $2,000...
17h ago
Tech Corner: AAPL Builds Up Tech Ecosystem
18h ago
StoxPulse AI results for XRTX: Pulse Score 56/100. Primary sentiment trends from 15 news sources and 0 SEC filings indicate a bullish outlook.
Market Cap
$598K
P/E Ratio
-0.2
EPS
$-0.65
Volume
92K
Avg Volume
—
Open
$0.39
Prev. Close
$0.42
Day Range
$0.37 - $0.46
50-Day Avg
$0.43
200-Day Avg
$0.67
52W High
$1.41
52W Low
$0.34
1D
+1.3%
5D
+12.7%
1M
-1.0%
3M
-29.6%
6M
-46.3%
YTD
-24.6%
1Y
-51.2%
3Y
-91.3%
5Y
-99.0%
Revenue
0.0%
Net Income
18.2%
EPS
50.6%
Free Cash Flow
23.2%
FY 2025 vs FY 2024
Outstanding
1.4M
Float
1.3M
Free Float
89.8%
Jan 14
$0.00
Oct 13
$0.00
Jul 13
$0.00
Apr 13
$0.00
Dec 12
$0.00
Oct 12
$0.00
Jul 12
$0.00
Apr 12
$0.00
Feb 12
$0.00
Nov 11
$0.00
Aug 11
$0.00
Stock Splits
Aug 24
+112.0%
Nov 24
+47.8%
May 25
May 25
-359.3%
Aug 25
+24.0%
Nov 25
+58.9%
Feb 26
+46.1%
May 26
Beat estimates 8 of 12 quarters (67%)
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

How Much Would You Have if You Had Invested $2,000 In Apple When It Went Public?

Tech Corner: AAPL Builds Up Tech Ecosystem

Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years?

The Fed Held Rates Again: Why Long-Term Investors May Not Need to Do Anything

Apple at 50: The iPhone maker 'blew a 5-year lead' on AI, but former insiders say it can still win

2,057 Shares in Apple Inc. $AAPL Acquired by Demming Financial Services Corp ADV

Apple Inc. $AAPL Stake Increased by Stableford Capital II LLC

Signal Advisors Wealth LLC Acquires 50,263 Shares of Apple Inc. $AAPL